Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
MerLion Pharma (Germany) · Clovis Oncology (United States) · +1 more institution
Abstract
Abstract Purpose Fibroblast activation protein (FAP) is a membrane-bound protease that has limited expression in normal adult tissues but is highly expressed in the tumor microenvironment of many solid cancers. FAP-2286 is a FAP-binding peptide coupled to a radionuclide chelator that is currently being investigated in patients as an imaging and therapeutic agent. The potency, selectivity, and efficacy of FAP-2286 were evaluated in preclinical studies. Methods FAP expression analysis was performed by immunohistochemistry and autoradiography on primary human cancer specimens. FAP-2286 was assessed in biochemical and cellular assays and in in vivo imaging and efficacy studies, and was further evaluated against…
Citation impact
- FWCI
- 21.94
- Percentile
- 100%
- References
- 50
Authors
21Topics & keywords
- Fibroblast activation protein, alpha
- Radionuclide therapy
- Medicine
- Radionuclide imaging
- Nuclear medicine
- Medical physics
- Internal medicine
- Cancer
- Good health and well-being